Bottom-up solution identifies proven brain mechanisms linked to PTSD, previously unknown 

Increased success rates in drug candidate selection, i.e. modulators of the body's own cannabinoid system

Generates evidence-based testable hypotheses to develop personalized PTSD treatments

Target PTSD subtypes instead of treating PTSD as unitary disorder

Allows more targeted clinical trials with enhanced sensitivity

Multi-modal biomarker strategy optimizes sample size

Support go/no-go decisions in more targeted clinical trials reducing patient risk exposure, time and costs during clinical development

Our approach allows drug development at lower risks and costs through enhanced signal detection

Combining state-of-the-art validated clinical interviews and novel biomarkers improves treatment responsiveness prediction

Employ evidence-based optimization of clinical trial designs leading to treatment personalization

Create more opportunities for success